Introduction {#S1}
============

Since the first report of fatigue being a prevalent and significant problem in multiple sclerosis (MS) ([@B1]) the definition, accurate quantification of fatigue in MS, and etiology has perplexed investigators. To date, nearly every article pertaining to MS-related fatigue contains some sort of disclaimer regarding our inadequate definition, lack of appropriate assessment tools, and limited understanding of its etiology ([@B2]). The present article is no exception. However, the investigation outlined in this paper is a replication of previous work demonstrating the fact that when attempting to at least better understand the *etiology* of fatigue in MS, consideration should be given to the role that sleep disturbance as it has been proven to be a significant factor ([@B3]).

Despite being the most obvious factor, sleep disturbance or disorders, had initially received fairly little attention as a precipitating or exacerbating factor of fatigue in MS. Fortunately, following an editorial by Attarian titled, "Importance of sleep in the quality of life of multiple sclerosis patients: a long under-recognized issue" sleep disturbance and its disorders have received significantly more attention ([@B4]). In fact, when conducting a PubMed search with the terms "MS" and "sleep" in the title, 14 articles have been published between the years 1987 and 1997 and 15 articles were dated from 1998 to 2008, suggesting approximately 15 published articles on sleep in MS per decade. However, since Attarian's editorial in 2009 the number of published articles with MS and sleep in the title is 46. Thus, at this rate, the number of published articles on sleep in MS over the past 5 years is one a half times more than what was published in the preceding two decades of the 2009 editorial (see Figure [1](#F1){ref-type="fig"}).

![**Number of articles published in PubMed with the words "sleep" and "multiple sclerosis" in the title**.](fneur-06-00021-g001){#F1}

These articles have been published worldwide and span the gamut of looking at the incidence of various sleep disorders to the role of sleep on quality of life and fatigue to the effects of treating sleep problems in MS. While the majority of these studies rely on self-report measurement, some have also included more objective measures including polysomnography. What is to follow is a brief review of fatigue in MS, the prevalence and nature of sleep disorders in MS, and the relationship between the two. Study findings from a recent investigation that replicates previous work demonstrating that sleep disturbance is a significant contributor to fatigue in MS when taking into account disease variables, depression, and sleep disturbance is then presented. Finally, data from a few studies that have demonstrated that effective treatment of such sleep problems can result in reduced fatigue among individuals with MS are provided.

Background {#S2}
==========

Fatigue in MS {#S2-1}
-------------

Fatigue is a frequent and debilitating symptom of MS with rates ranging anywhere from 53 to 90% ([@B1], [@B5]--[@B9]). MS-related fatigue has typically been construed as being either primary or secondary. Primary fatigue is purported to be related to centrally mediated processes of the disease, such as demyelination and axonal loss in the central nervous system or immunological factors. Secondary fatigue, on the other hand, is thought to be a result of the host of factors that may accompany MS (e.g., depression, reduced activity, medication side effects, sleep disturbance) ([@B10]). The present paper focuses on secondary fatigue and the role of sleep disturbance. However, regardless of the exact etiology, fatigue is known to be extremely detrimental to those with MS with nearly 55% of patients reporting fatigue to be among their worst symptoms ([@B11]) and 40% describing it as their most disabling symptom ([@B8]). MS-related fatigue has also been shown to have detrimental effects on daily functioning, social and occupational obligations, and overall well-being. In fact, Freal et al. showed that of the 87% of MS patients complaining of significant fatigue, 67% reported experiencing it on a daily basis and 22% reported that it interfered with their daily functioning ([@B1]). Similarly, Iriarte et al. found that fatigue produced limitations in daily functioning in 66% of those who complained of fatigue ([@B12]). Of this, 37% reported that it limited their social activities and 61% reported that fatigue limited their work. This is consistent with reports showing that fatigue leads to patients having to cut down on working hours ([@B13]) and findings that individuals with MS report fatigue as the one of the greatest culprits related to work difficulty or leaving the workforce ([@B14]). Patients also report that their fatigue can result in a lowered sense of self-worth as well as feelings of shame, sorrow, and anger related to their perceptions of their fatigue ([@B15]). Similarly, fatigue in MS has been shown to be related to lowered positive affect, psychological distress, and a sense of loss of control ([@B16]). Given its grave impact, identification of factors associated with fatigue has been a main priority in research and clinical care among individuals with MS.

Sleep disorders in MS {#S2-2}
---------------------

Current research suggests that anywhere from 19 to 67% of individuals with MS experience some sort of sleep difficulty ([@B17]--[@B32]), with rates as high as 80% in some samples ([@B33]). Restless leg syndrome (RLS) ([@B27], [@B28], [@B30]), periodic limb movement (PLM) ([@B21]), narcolepsy--cataplexy syndrome, rapid eye movement (REM) behavior disorder, insomnia, and obstructive sleep apnea (OSA) ([@B34]) have all been reported (see Table [1](#T1){ref-type="table"}).

###### 

**Prevalence of sleep disorders in multiple sclerosis (MS)**.

  Reference                          Country   Size   Disorder(s)                                        Prevalence MS   Controls
  ---------------------------------- --------- ------ -------------------------------------------------- --------------- ----------
  Bamer et al. ([@B17])              USA       1062   Disturbed sleep[^a^](#tfn1){ref-type="table-fn"}   52%             --
  Lunde et al. ([@B26], [@B35])      Norway    90     Poor sleep[^b^](#tfn2){ref-type="table-fn"}        67%             44%
  Merlino et al. ([@B29])            Italy     120    Poor sleep[^b^](#tfn2){ref-type="table-fn"}        48%             --
  Chen et al. ([@B19])               China     21     Poor sleep[^b^](#tfn2){ref-type="table-fn"}        62%             --
                                                      Initial insomnia                                   43%             
                                                      Middle insomnia                                    76%             
                                                      Terminal insomnia                                  33%             
  Pokryszko-Dragan et al. ([@B31])   Poland    100    Initial insomnia                                   28%             --
                                                      Middle insomnia                                    33%             
                                                      Terminal insomnia                                  48%             
  Stanton et al. ([@B32])            USA       60     Initial insomnia                                   42%             --
  Braley et al. ([@B33])             USA       30     Obstructive sleep apnea                            80%             63%
  Kaminska et al. ([@B23])           Canada    62     Obstructive sleep apnea                            58%             47%
  Dias et al. ([@B20])               USA       103    Obstructive sleep apnea                            42%             --
  Braley et al. ([@B18])             USA       195    Obstructive sleep apnea                            21%             --
  Kallweit et al. ([@B22])           Germany   69     Sleep disordered breathing                         41%             
  Manconi et al. ([@B27])            Italy     861    Restless legs syndrome                             19%             4%
  Manconi et al. ([@B27])            Italy     82     Restless legs syndrome                             37%             --
  Moreira et al. ([@B30])            Italy     44     Restless legs syndrome                             27%             --
  Kaminska et al. ([@B23])           Canada    62     Restless legs syndrome                             27%             6%
  Kaynak et al. ([@B7], [@B24])      Turkey    37     Restless legs syndrome                             38%             0
  Ferini-Strambi et al. ([@B21])     Italy     25     Periodic limb movement                             36%             8%
  Kaminska et al. ([@B23])           Canada    62     REM sleep behavior                                 3%              0
  Kaminska et al. ([@B23])           Canada    62     Narcolepsy                                         2%              0

*^a^Based on the medical outcome study sleep (moss) scale*.

*^b^Based on the Pittsburgh sleep quality index*.

In general, it is believed that individuals with MS are three times more likely to experience sleep difficulties than controls ([@B36]), though the incidence may be greater for some disorders. For instance, in a large study consisting of 861 individuals with MS and 649 healthy controls, it was found that the risk for RLS was 5.4 times greater for individuals with MS ([@B28]).

For many sleep disorders, a direct neurological etiology associated with MS has been found. For instance, cervical lesions have been found to be associated with RLS ([@B27]) while greater lesion load in the brainstem and cerebellum has been implicated in PLM ([@B21]). Narcolepsy in MS has been suggested to be related to focal lesions in the hypothalamus ([@B37]). Finally, REM-behavior sleep disorders in MS have been linked to dorsal pontine lesions ([@B37]). While these sleep disorders have a direct etiology related to specifically to MS, insomnia, and OSA, which are also common in the general public have been found to be more prevalent in MS. Insomnia in MS has been attributed to a multitude of factors, primarily nocturia, leg spasms, muscle stiffness, pain, depression, and symptomatic MS medication side effects ([@B32], [@B38]). It has been previously shown that individuals report bladder incontinence as the greatest contributor to disturbed sleep, followed by muscle stiffness and leg spasms, in more than 50% of patients ([@B38]). Similar findings were found by Stanton et al. in which nocturia was the most common cause of middle insomnia (72%), followed by pain/discomfort (22%). Nocturia was also the greatest contributor to terminal insomnia (40%), while anxiety/racing mind accounted for initial insomnia most often (28%). In general, depression has been shown to be more related to initial insomnia, while nocturia has been found to be the cause of middle and terminal insomnia ([@B32]). With regard to OSA, again, reports of OSA in MS are as high as 80% compared to 63% of healthy controls. Causes of OSA in MS may include inactivity due to disability, brainstem lesions that affect the respiratory centers or nucleus ambiguous, or symptomatic medications that relax muscle tone in the pharynx ([@B37]). While these sleep disorders are perhaps the most prevalent in MS, they are both amenable to treatment as will be discussed.

Relationship of fatigue and sleep in MS {#S2-3}
---------------------------------------

Nearly all studies examining sleep problems in MS have been an attempt to understand its relationship to secondary fatigue and potential mediating effects, with a few exceptions. In particular, a number of studies in the MS literature have focused on sleep disturbance as a significant contributor to fatigue in MS ([@B23], [@B24], [@B30], [@B32], [@B39]--[@B41]). For instance, when comparing fatigued and non-fatigued individuals with MS, Kaynak et al. found that those suffering from fatigue experience greater disturbance in sleep microstructure such as total arousal index (TAI), a measure of sleep fragmentation, and PLM index ([@B24]). Such findings are consistent with Chen et al.'s findings in which fatigue scores correlated with PLM index, PLM arousal index, REM latency, and TAI ([@B19]). Moriera et al.'s study also found that individuals diagnosed with RLS reported poorer sleep quality, which was in turn related to fatigue ([@B30]). Finally, reports on a self-report measure of OSA have also been shown to be related to reports of fatigue with more fatigued individuals being more likely to have elevated scores on this measure, even when items that could be construed as fatigue were removed ([@B18], [@B20]).

When constructing a model of fatigue in MS that took into account disease severity, sleep, and depression, it was found that sleep disturbance was the greatest predictor of fatigue, accounting for 24% of the variance followed by depression (10%) and disease severity (9%) ([@B3]). It should be noted that this study utilized measures in which overlapping items of fatigue, sleep, and depression were removed from the measures so as to have the purest constructs. These findings were later replicated by Ghajarzadeh et al. in an Iranian sample in which sleep disturbance accounted for 25% of the variance and depression accounted for an additional 9% ([@B42]). Such findings suggest that sleep may be the greatest culprit in the experience of fatigue in MS. Within, present findings demonstrate an additional, third replication of these findings in hopes of furthering the increase in attention to sleep problems in MS and their contribution to fatigue in MS.

Research Design and Methods {#S3}
===========================

Participants {#S3-4}
------------

Participants were recruited from local MS clinics and chapters of the National Multiple Sclerosis Society throughout United States. Participants were enrolled in a larger study examining factors associated with employment in MS and thus were all employed, between the ages of 20 and 64, and diagnosed with definite MS.

Procedures {#S3-5}
----------

Participants completed an online survey consisting of several measures assessing disease variables, psychological functioning, well-being, health--behaviors, adjustment and coping to MS, and overall quality of life. All procedures were approved by the Institutional Review Board of the Kessler Foundation. For the purposes of the present study, participants completed the following measures.

Measures {#S3-6}
--------

### Modified fatigue impact scale {#S3-6-1}

Modified fatigue impact scale (MFIS) is modified form of the fatigue impact scale ([@B43]) that is based on 21 items derived from interviews with MS patients concerning how fatigue impacts their lives. It consists of three subscales: physical, cognitive, and psychosocial functioning. Patients are asked to rate on a scale of 0--4 their agreement with the statement and how it impacts them with "0" being "Never" and "4" being "Almost always." Recently, it has been recommended that a cutoff of 38 on the MFIS was most indicative of significant fatigue in MS ([@B44]). Given the potential overlap of fatigue and depressive symptoms on the psychosocial subscale, the sum of the physical and cognitive subscales was used for the regression analyses. This score has been termed the MFISPC.

### Pittsburgh sleep quality index {#S3-6-2}

The Pittsburgh sleep quality index (PSQI) is a measure of sleep disturbance and quality ([@B45]). It consists of 19 items that are summed to create seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, daytime dysfunction, and use of sleeping medication. The sum of scores for these seven components yields one global score. A cutoff of "5" on the global score is indicative of being a "poor" sleeper. The global score was used in all analyses.

### Chicago multiscale depression inventory {#S3-6-3}

The Chicago multiscale depression inventory (CMDI) was specifically designed to assess depression in MS and other medical groups ([@B46]). It consists of three subscales: evaluative, mood, and vegetative. Each subscale contains 14 items and patients are asked to rate on a scale of 1--5 the extent to which each word/phrase describes them during the past week, including today with "1" being "Not at All" and "5" being "Extremely." For the purpose of this study, ratings on the vegetative scale were removed due to confounds of sleep and fatigue included in the items on this scale. For our sample, depression was measured by a total score of only the combined evaluative and mood subscales. This score has been termed the CMDIME.

Statistical analyses {#S3-7}
--------------------

All statistical analyses were conducted using SPSS 21.0 computer software. Pearson correlations were conducted for all correlational analyses. Independent *t*-tests were conducted to examine group differences between the sleep disturbed and non-sleep disturbed groups on demographics, disease variables, fatigue, and depression. Finally, a stepwise, hierarchical regression was conducted with disease duration, sleep disturbance, and depression as the independent variables and fatigue as the dependent variable.

Results {#S4}
=======

A total of 107 individuals with definite MS were enrolled in the study. Participants were primarily female (*N* = 92; 86%) with a mean age of 44.71 (±9.76) and mean disease duration of 8.91 (±7.13). Per the global score of the PSQI, 61% of participants were classified as "poor sleepers" and constitute the "sleep disturbed" group. Per the previously recommended cutoff of 38 on the MFIS, approximately half of the sample (47%) experienced significant fatigue (see Table [2](#T2){ref-type="table"}).

###### 

**Participant demographics and group comparisons on disease variables, sleep, fatigue, depression**.

                             Total sample (*N* = 107) mean (SD)             Range                                      
  -------------------------- ---------------------------------------------- ------------------------------------------ ---------------------------
  Age                        44.71 (9.76)                                   23--64                                     
  Disease duration           8.91 (7.13)                                    0--31                                      
  PSQI total                 7.07 (4.07)                                    1--18                                      
  MFIS physical              17.47 (8.00)                                   0--35                                      
  MFIS cognitive             16.00 (9.34)                                   0--38                                      
  MFIS psychosocial          3.40 (1.92)                                    0--8                                       
  CMDI mood                  22.83 (10.07)                                  14--68                                     
  CMDI evaluative            19.38 (8.19)                                   14--61                                     
  CMDI vegetative            33.70 (9.72)                                   17--53                                     
                                                                                                                       
                             **Not sleep disturbed (*N* = 42) mean (SD)**   **Sleep disturbed (*N* = 65) mean (SD)**   ***t*-test, sig**.
                                                                                                                       
  Age                        46.00 (10.32)                                  43.88 (9.36)                               *t* = 1.10, *p* = 0.274
  Disease duration           8.19 (6.07)                                    9.38 (7.75)                                *t* = −0.84, *p* = 0.401
  PSQI sleep duration        0.24 (0.43)                                    0.95 (0.99)                                *t* = −5.12, *p* \< 0.001
  PSQI sleep disturbances    1.12 (0.45)                                    1.60 (0.49)                                *t* = −5.18, *p* \< 0.001
  PSQI sleep latency         0.50 (0.59)                                    1.49 (0.89)                                *t* = −6.93, *p* \< 0.001
  PSQI daytime dysfunction   0.74 (0.63)                                    1.48 (0.77)                                *t* = −5.42, *p* \< 0.001
  PSQI sleep efficiency      0.10 (0.48)                                    1.11 (1.25)                                *t* = −5.88, *p* \< 0.001
  PSQI sleep quality         0.60 (0.50)                                    1.65 (0.80)                                *t* = −8.39, *p* \< 0.001
  PSQI sleep medication      0.24 (0.66)                                    1.20 (1.29)                                *t* = −5.08, *p* \< 0.001
  PSQI global score          3.36 (1.27)                                    9.48 (3.38)                                *t* = −1.50, *p* \< 0.001
  MFIS physical              14.81 (7.82)                                   19.18 (7.70)                               *t* = −2.84, *p* = 0.006
  MFIS cognitive             12.62 (7.47)                                   18.18 (9.82)                               *t* = −3.31, *p* = 0.001
  MFIS psychosocial          2.79 (1.88)                                    3.80 (1.85)                                *t* = −2.75, *p* = 0.007
  CMDI mood                  21.02 (9.85)                                   24.00 (10.11)                              *t* = −1.50, *p* = 0.136
  CMDI evaluative            18.26 (8.14)                                   20.10 (8.20)                               *t* = −1.14, *p* = 0.257
  CMDI vegetative            28.07 (5.22)                                   37.34 (10.24)                              *t* = −6.16, *p* \< 0.001

*PSQI, Pittsburgh sleep quality index; MFIS, modified fatigue impact scale; CMDI, Chicago multiscale depression inventory*.

Initial correlations found physical and cognitive fatigue to be significantly correlated with poor sleep (*r* = 0.42 and 0.49, *p* \< 0.001, respectively). A slightly lower correlation was found with psychosocial fatigue (*r* = 0.30, *p* = 0.001). Fatigue was also found to be associated with all of the subscales of the CMDI (*r*'s ranging from 0.24 to 0.72), with the highest correlations occurring with the vegetative subscale (*r*'s ranging from 0.47 to 0.72), which is expected given the overlap of fatigue items on the vegetative scale. Finally, sleep was not found to be related to the mood or evaluative subscales of the CMDI but was significant correlated with the vegetative subscale (*r* = 0.65, *p* \< 0.001). Again, this is greatly influenced by item overlap. When looking at the measure scores used in the regression analyses (MFISPC and CMDIME) the correlations between fatigue, depression, and sleep remained (see Table [3](#T3){ref-type="table"}).

###### 

**Correlations of fatigue, depression, and sleep disturbance**.

                 Mood                                     Evaluative                               Vegetative                               Sleep                                    MFISPC
  -------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ----------------------------------------
  Physical       0.32[\*\*](#tfn4){ref-type="table-fn"}   0.29[\*\*](#tfn4){ref-type="table-fn"}   0.50[\*\*](#tfn4){ref-type="table-fn"}   0.42[\*\*](#tfn4){ref-type="table-fn"}   --
  Cognitive      0.33[\*\*](#tfn4){ref-type="table-fn"}   0.24[\*](#tfn3){ref-type="table-fn"}     0.72[\*\*](#tfn4){ref-type="table-fn"}   0.49[\*\*](#tfn4){ref-type="table-fn"}   --
  Psychosocial   0.37[\*\*](#tfn4){ref-type="table-fn"}   0.29[\*\*](#tfn4){ref-type="table-fn"}   0.47[\*\*](#tfn4){ref-type="table-fn"}   0.30[\*\*](#tfn4){ref-type="table-fn"}   --
  Mood           --                                       --                                       --                                       0.14                                     --
  Evaluative     --                                       --                                       --                                       0.13                                     --
  Vegetative     --                                       --                                       --                                       0.65[\*\*](#tfn4){ref-type="table-fn"}   --
  MFISPC         --                                       --                                       --                                       0.51[\*\*](#tfn4){ref-type="table-fn"}   --
  CMDIME         --                                       --                                       --                                       0.14                                     0.34[\*\*](#tfn4){ref-type="table-fn"}

*Physical, MFIS physical subscale; Cognitive, MFIS cognitive subscale; Psychosocial, MFIS psychosocial subscale; Mood, CMDI mood subscale; Evaluative, CMDI evaluative subscale; Vegetative, CMDI vegetative subscale; Sleep, PSQI global score; MFISPC, MFIS Physical + Cognitive score; CMDIME, CMDI Mood + Evaluative score*.

*\*Significant at the 0.05 level*.

*\*\*Significant at the 0.01 level*.

Stepwise regression analyses found that sleep disturbance accounted for 25% of the variance in predicting fatigue, followed by depression, which accounted for an additional 7%. Together, they accounted for 32% of the variance, while disease duration did not contribute to predicting fatigue (see Table [4](#T4){ref-type="table"}).

###### 

**Stepwise hierarchical regression predicting fatigue with disease duration, sleep, and depression as the independent variables**.

               *B*    SE (*B*)   β                                        *R*^2^
  ------------ ------ ---------- ---------------------------------------- --------
  **Step 1**                                                              
   PSQI        1.95   0.32       0.51[\*\*](#tfn5){ref-type="table-fn"}   0.25
  **Step 2**                                                              
   PSQI        1.80   0.31       0.47[\*\*](#tfn5){ref-type="table-fn"}   
   CMDIME      0.24   0.07       0.28[\*\*](#tfn5){ref-type="table-fn"}   0.32

*PSQI, Pittsburgh sleep quality index global score; CMDIME, Chicago multiscale depression inventory mood and evaluative subscales*.

*\*\*Significant at the 0.01 level*.

Such findings are a near replication of previous findings, suggesting that sleep disturbance is the greatest predictor of fatigue in MS when examined among disease variables and depression, and accounts for a quarter of the variance. However, it should be noted that there are limitations of the present data, including the lack of objective measures of disease severity, fatigue, and sleep disturbance and the use of self-report surveys. There is also the lack of information pertaining to participants' medication load. Such factors may also contribute to sleep problems in MS. Though, even with the limitations of the present data, clinical findings, and research supporting, the significant role of sleep on MS-related fatigue should hopefully compel practitioners to consider more routine assessment of sleep and referral to sleep studies, when warranted, or when presented with a patient complaining of significant, debilitating fatigue that may exceed what one expects in MS. Consideration should also be given when there is any indication from the patient or bed partner that they patient may have a concomitant sleep disorder. Lunde et al. provide a very thorough review of how best to begin to assess sleep problems in MS as there are presently no specific guidelines. Practitioners are urged to refer to the full guidelines provided by Lunde et al. when treating individuals who complain of significant fatigue, daytime sleepiness/dysfunction, and sleep difficulties. We turn now to a brief discussion pertaining to the findings that proper assessment and treatment of sleep problems in MS may result in reduced fatigue.

Treating sleep problem in MS {#S4-8}
----------------------------

Additional support for addressing sleep problems as an underlying cause of fatigue is more recent findings that effective treatment of sleep problems actually results in reductions in self-reported fatigue and sleepiness in MS. More specifically, in a controlled, non-randomized clinical study, Cote et al. evaluated 62 individuals with MS and referred those suspected of having a sleep disorder for evaluation and treatment at a sleep disorder clinic. Of the 39 (63%) who were diagnosed with a sleep disorder, 21 were treated and 18 were not. Treatment consisted of sleep hygiene advice and then further treatment, which was dependent on the nature of the sleep disorder and included continuous positive airway pressure (CPAP) or other position devices for sleep apnea; treatment of exacerbating factors (e.g., iron or B12 deficiency) and/or pramipexole for RLS; clonazepam for REM behavior disordered sleep; and cognitive behavioral therapy for insomnia. Three months follow-up revealed a significant improvement in fatigue as well as sleepiness, subjective sleep quality, depression, pain, and quality of life among those who were treated. Those not treated did not demonstrate such improvement ([@B39]). In another study, progressive muscle relaxation was also shown to improve sleep quality and reports of fatigue in a sample of 32 individuals with MS ([@B47]). More specifically, the average score of the fatigue severity scale ([@B48]) decreased from 5.75 ± 0.95 (a score above the recommended cutoff of 4) to 3.81 ± 1.30 (*p* \< 0.001). Finally, Veauthier et al. evaluated the effectiveness of compliance with treatment imposed by a sleep specialist in 42 individuals with MS. Those who were described as having "good compliance" to the treatment demonstrated a significant, 15-point difference on the MFIS. Such significant findings were not found in those with no to moderate compliance or those without a sleep disorder that were followed over the same time period ([@B40]). While it is possible, there may be some expectation bias among those that adhere to their treatment and subsequent ratings of improvement, it should be noted that those who were partially compliant to their treatment also demonstrated an improvement in fatigue, albeit not statistically significant. Together, these findings further stress the importance of proper assessment and effective treatment of sleep problems among individuals with MS complaining of significant fatigue and suggest that effective assessment, referral, and treatment of sleep problems in MS are likely to yield significant results.

In sum, the present paper aimed to again increase our awareness of the prevalence and etiology of sleep problems in MS and more importantly, its contribution to the experience of fatigue, one of the most disabling symptoms associated with MS. The study described within also provides further support of the role of sleep on fatigue and the importance of its assessment. In science, observation is the first step in questioning and aiming to understand a phenomenon. MS-related fatigue has been a construct that has perplexed investigators for decades. Over the past few years, the field has begun to test the hypothesis that sleep may be a significant contributor of fatigue in MS. These observations and subsequent findings have yielded positive results. However, the next, and sometimes neglected aspect of science, is replication. Here, findings show a third replication of study findings that consistently demonstrate that sleep problems account for approximately a quarter of the variance of fatigue in MS.

Based on these findings, further research is warranted in which we continue to examine and model the contributing factors of fatigue and sleep in MS in hopes of indentifying the factors and ultimately, treating them. In doing so, future studies should address some of the methodological limitations of past studies, including reliance on self-report measures of sleep and fatigue. Objective measurement of sleep and fatigue, while time consuming and costly, are likely to yield more substantial findings. A few preliminary studies demonstrating the effects of treating sleep on fatigue were also provided within. Further intervention studies are warranted with larger sample sizes and great characterization of the sleep problems as well as the active ingredients of treatment. With such advances, it is hoped that we will see an increase in the assessment, referral, evaluation, and treatment of sleep problems in MS and ultimately be capable of improving the lives and well-being of individuals with MS.
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